Home » News » OncoInv and OnkoDiag join forces to make multi cancer early detection available in Poland
OncoInv and OnkoDiag join forces to make multi cancer early detection available in Poland
April 10, 2024
OncoInv and OnkoDiag join forces to make multi cancer early detection available in Poland with OncoSeek

In Poland, cancers are detected in late stages, which makes effective treatment impossible. OnkoDiag places great emphasis on cancer prevention and that’s why they have chosen OncoSeek® for its offer. OncoSeek® is a patient-friendly product to detect cancer as it requires only a blood sample. It’s a modern solution that will aid early cancer diagnosis which is key to the treatment of oncological disease. 

OnkoDiag states: “The OncoSeek® test is a test for early cancer screening at an affordable price for patients. Thanks to OncoSeek®, we will be able to introduce a comprehensive product that will allow for the quick detection of cancer and, consequently, early implementation of oncological treatment and a greater chance of survival. The OncoSeek® study was thoroughly analysed by us and consulted with many specialists. Our company is proud to be able to work with OncoInv on this project.” 

OnkoDiag has been cooperating with the best laboratories in Poland for years, providing patients in Poland with access to the most modern laboratory diagnostics. When choosing their partners, the company is guided primarily by high quality and detailed clinical research. Thanks to this selection, patients of OnkoDiag have access to the best products. OnkoDiag and OncoInv now join forces and look forward to working together to allow quick detection of cancer in Poland. 

About OncoSeek® 

Blood samples are analysed on 7 Protein Tumour Markers (PTM). The resulting data is processed by cloud-based software using Artificial Intelligence and big data to analyse the resulting data sets. The algorithm is operated by OncoInv and is fully GDPR compliant. 

OncoSeek® covers the most common aggressive cancers and its specificity and sensitivity are considered better than traditional approaches in the realm of early detection and diagnosis. 

OncoSeek® has been developed by SeekIn (China, US). SeekIn has partnered with OncoInv to make its products available to as many countries as possible. To fulfil this ambition OncoInv offers the products at low cost. 

About OnkoDiag 

Onkodiag.pl is an innovative company specialising in genetic tests and analysis of circulating cancer cells. OnkoDiag has been providing modern genetic diagnostics for oncology patients in Poland for over 10 years. Their goal is to design the most effective treatment for cancer patients by understanding the unique characteristics of their tumours. Their work is aimed at improving treatment results and the quality of life of cancer patients. Their mission is to facilitate access to diagnostics enabling personalised oncological treatment and early diagnosis of cancer. For more information visit https://onkodiag.pl  

About OncoInv 

OncoInv is based in Houten, the Netherlands. The mission of OncoInv is to make multi-cancer early detection solutions available to as many people as possible, thus improving the outcome for patients and their families. OncoInv offers its products and services on a not-for-profit basis in Low- and Middle-Income countries to ensure high availability by minimizing the costs. OncoInv is a fully owned subsidiary of the non-profit foundation Inspire2Live. For more information, please continue your visit to our website.

About SeekIn 

SeekIn is a biotech company founded in early 2018 in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing -generation sequencing and artificial intelligence. Since founded, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn also developed novel molecular tests for leukaemia patients. With its proprietary technical advances, SeekIn has launched several research and clinical studies in collaboration with top-tier hospitals. SeekIn envisions that by leading a new norm for cancer early detection the clinical outcome of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%. For more information about SeekIn’s cutting-edge technologies and products, visit www.seekincancer.com 

About Inspire2Live 

Inspire2Live is an international patient advocacy organisation operating on an international level. They are on a mission to inspire and empower patients, researchers and clinicians to work together to prevent, treat and eliminate cancer. “If we all believe that healthcare should be for the benefit of patients, then we should be part of the discussion and the decision process: When about us, not without us.” Inspire2Live achieve their goals by connecting stakeholders in the medical industrial complex and organising congresses and discovery networks. These connections have led to many initiatives which are transforming the way research and healthcare work to become more patient-centric. They operate globally in full respect of local considerations. For more information, please visit www.inspire2live.org 

More news